Encodes A Microbial Polypeptide Patents (Class 536/23.7)
  • Patent number: 9834773
    Abstract: Described are methods and means for metabolic engineering and improved product formation by a filamentous micro-organism or a low G+C gram-positive bacterium. Disclosed is that DasR and DasR binding sites play an important and universal role in the control of gene expression in micro-organisms. Based on this finding, provided are multiple useful applications, such as a method for regulating the expression of a gene of interest, a method for controlling metabolism, a method for decreasing undesired expression and many more. Moreover, provided are means that can be used to establish said methods: for example a micro-organism in which the DasR binding site in operable linkage with a particular gene has been modified to obtain increased or decreased expression of a protein (being a desired or undesired protein) encoded by said gene.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: December 5, 2017
    Assignees: Universiteit Leiden, University of Liège, Friedrich-Alexander-Universität Erlangen-Nürnberg
    Inventors: Sebastien Rigali, Mannfred Friedrich Bruno Titgemeyer, Gilles Philippus Van Wezel
  • Patent number: 9745575
    Abstract: The present invention refers to antagonist molecules, particularly nucleic acid effector molecules directed against a bacterial RNA.
    Type: Grant
    Filed: June 17, 2009
    Date of Patent: August 29, 2017
    Assignee: National University of Singapore
    Inventor: Volker Patzel
  • Patent number: 9446112
    Abstract: The invention relates to compositions and methods for treating C. difficile associated disease (CDAD) through the administration to a subject in need thereof at least one nucleic acid encoding at least a portion of at least one of toxin A and toxin B.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: September 20, 2016
    Assignees: Philadelphia Health & Education Corporation, Inovio Pharmaceuticals, Inc., The Trustees of the University of Pennsylvania
    Inventors: Michele Kutzler, Scott Baliban, David B. Weiner, Niranjan Y. Sardesai, J. Joseph Kim
  • Patent number: 9399673
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: July 26, 2016
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • Patent number: 9382546
    Abstract: There is described a method of synthesizing a family of oligopeptides of predetermined amino acid sequence, which together make up from 7 amino acids to the complete amino acid sequence of a target protein, which comprises: synthesizing a nucleic acid construct which codes for a fusion protein composed of overlapping peptides derived from the desired portion of the target protein, interspersed with regions which code for protease cleavage sites, expressing the nucleic acid construct in a suitable expression vector, harvesting the fusion protein corresponding to the nucleic acid sequence, and digesting the fusion protein with a protease selective for the cleavage sites to generate the oligopeptides. The oligopeptides may be generated in vitro or in vitro and may be used as vaccines against viral infections and in epitope mapping.
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: July 5, 2016
    Assignees: ISIS INNOVATION LTD., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Shisong Jiang, Ruth Ruprecht
  • Patent number: 9308248
    Abstract: The present invention relates to means and methods to protect against disease caused by bacteria belonging to the genus Chlamydia. In particular, the present invention relates to isolated B- and T-cell epitopes derived from the major outer membrane protein of Chlamydia psittaci which can be used against an infection with a species of the genus Chlamydia. More in particular, the invention provides a vaccine which can be used against chlamydiosis caused by Chlamydia psittaci in birds and man. In addition, the invention relates to a diagnostic method to diagnose the latter infections.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: April 12, 2016
    Assignee: Universiteit Gent
    Inventor: Daisy Vanrompay
  • Patent number: 9273307
    Abstract: The invention relates to global transcription machinery engineering to produce altered cells having improved phenotypes.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: March 1, 2016
    Assignee: Massachusetts Institute of Technology
    Inventors: Hal S. Alper, Gregory Stephanopoulos
  • Patent number: 9249196
    Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: February 2, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Claire Fraser, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
  • Patent number: 9222110
    Abstract: The present invention relates generally to compositions and methods for producing lactic acid using a lactic acid producing microorganism. More specifically, the present invention relates to methods for producing lactic acid with high yield, high concentration and high volumetric productivity through biological fermentation by Enterococcus faecalis, or recombinant microorganisms transformed to produce lactate dehydrogenase using the lactate dehydrogenase-encoding genes derived from E. faecalis.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: December 29, 2015
    Assignee: South Dakota Board of Regents
    Inventors: Lew P. Christopher, Mohanraj Subramanian, Suvarna Naga Lavanya Talluri
  • Patent number: 9193771
    Abstract: The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a Neurotoxin polypeptide exhibiting a reduced duration of biological effect in a subject, wherein the polypeptide comprises at least one degradation signal in the light chain as well as vectors and host cells comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising the polynucleotides and polypeptides as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: November 24, 2015
    Assignee: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Fred Hofmann, Jurgen Frevert
  • Patent number: 9120868
    Abstract: A synthetic nucleotide, which transcribes as the cell-traversal protein for ookinetes and sporozoites (CelTOS) antigen of Malaria Plasmodium, and methods of use thereof.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: September 1, 2015
    Assignee: The United States of America as Represented by the Secratary of the Army
    Inventors: Evelina Angov, Elke Bergmann-Leitner, Christian Ockenhouse
  • Patent number: 9080191
    Abstract: The present invention relates to novel methods for biocatalytic production of nitriles from oximes using oxime dehydratases and novel mutants with oxime dehydratase activity and use thereof in a process for biocatalytic production of nitriles, such as in particular for the production of citral nitrile, neral nitrile, geranial nitrile or citronellyl nitrile from citral oxime, neral oxime, geranial oxime or citronellal oxime; and oxime dehydratases usable therefor, nucleotide sequences therefor and expression constructs or microorganisms comprising these.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: July 14, 2015
    Assignee: BASF SE
    Inventors: Andrea Piatesi, Wolfgang Siegel, Kai-Uwe Baldenius
  • Publication number: 20150147332
    Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: May 28, 2015
    Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
  • Publication number: 20150140026
    Abstract: The present disclosure relates to surface proteins of Moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines. The present disclosure also provides peptides interacting with fibronectin, laminin and the complement system.
    Type: Application
    Filed: October 7, 2014
    Publication date: May 21, 2015
    Applicant: ARNE FORSGREN AB
    Inventors: ARNE FORSGREN, KRISTIAN RIESBECK
  • Patent number: 9034642
    Abstract: The invention relates to the polynucleotide sequence of a nontypeable strain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: May 19, 2015
    Assignees: NATIONWIDE CHILDREN'S HOSPITAL, THE BOARD OF REGENTS OF UNIVERSITY OF OKLAHOMA
    Inventors: Lauren O. Bakaletz, Robert S. Munson, Jr., David W. Dyer
  • Publication number: 20150135343
    Abstract: Certain embodiments are directed to polypeptide sensors. Certain aspects of the invention are directed to polypeptides for sensing or detecting GTP and GTP concentrations. In further aspects, the polypeptide sensor can measure GTP concentrations, with high temporal and spatial resolution.
    Type: Application
    Filed: May 18, 2013
    Publication date: May 14, 2015
    Applicant: The Board of Regents of the University of Texas Sy
    Inventors: Rui Sousa, Mitra Rana
  • Publication number: 20150125503
    Abstract: The invention provides improvements of lantibiotics useful for reducing the numbers of microbes or the reproduction of microbes in or on subjects or objects. One embodiment of the invention provides variants of antibiotics wherein the amino acid at position (1) is changed to Ile or Gly, the amino acid at position (4) is changed to an Ala, the amino acid at position (4) is removed, the amino acid at position (5) is changed to an Ala, or wherein, as in the case of MU1140, the amino acid at position (13) is Arg, the Arg at position (13) is substituted with Asp, or combinations of two or more these changes or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 22, 2013
    Publication date: May 7, 2015
    Inventors: Jeffrey D. Hillman, James Leif Smith, Shawanda R. Wilson-Stanford
  • Patent number: 9024111
    Abstract: The present invention relates to nucleic acids, peptides, vectors, cells, and plants useful in the production of biofuels. In certain embodiments, the invention relates to nucleic acid sequences and peptides from extremophile organisms, such as SSO1949 and Ce1A, that are useful for hydrolyzing plant cell wall materials. In further embodiments, the invention relates to modified versions of such sequences that have been optimized for production in one or both of monocot and dicot plants. In other embodiments, the invention provides for targeting peptide production or activity to a certain location within the cell or organism, such as the apoplast. In further embodiments, the invention relates to transformed cells or plants. In additional embodiments, the invention relates to methods of producing biofuel utilizing such nucleic acids, peptides, targeting sequences, vectors, cells, and/or plants.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: May 5, 2015
    Assignee: Sandia Corporation
    Inventors: Joseph S. Schoeniger, Masood Zia Hadi
  • Publication number: 20150111298
    Abstract: The present invention provides a tomaymycin biosynthetic gene cluster of Streptomyces species FH6421, and its use for producing 11-de-O-methyltomaymycin.
    Type: Application
    Filed: May 13, 2013
    Publication date: April 23, 2015
    Applicant: Sanofi
    Inventors: Claus Lattemann, Mark Broenstrup, Stefan Werner, Rolf Müller, Kirsten Harmrols
  • Publication number: 20150111207
    Abstract: Sequences having specificity for Mycoplasma and related Mollicutes genus strains and uses thereof. Methods of use include detection of samples contaminated with Mycoplasma. Kits are provided and comprise one or more oligonucleotides for the detection of Mycoplasma and related Mollicutes genus strains.
    Type: Application
    Filed: May 31, 2013
    Publication date: April 23, 2015
    Inventors: Claudia Zylberberg, Juan Manuel Rodriguez, Andres Clemente Hernando Insua, Ricardo Ariel Lopez
  • Patent number: 9011878
    Abstract: The present invention relates generally to vaccine strains of Brachyspira hyodysenteriae. In particular, the present invention relates to isolated live vaccine strains of B. hyodysenteriae lacking one or more virulence factors. The present invention also relates to methods of identifying and preparing vaccine strains, as well as vaccine compositions against diarrhoeal diseases and methods and kits for diagnosing same.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: April 21, 2015
    Assignee: Spirogene Pty Ltd
    Inventors: David J. Hampson, Tom La, Matthew I. Bellgard, Nyree D. Phillips
  • Publication number: 20150105255
    Abstract: Derivatives of Agrobacterium vitis strain F2/5 are disclosed. These derivatives were generated following homologous recombination with an internal fragment of targeted genes resulting in gene disruption by insertion of a copy of suicide vector pVIK165. The genes disrupted were F-avi5813 encoding a phosphopantetheinyltransferase, F-avi4329 encoding an aminotransferase and F-avi0838 (rirA) encoding an iron responsive transcriptional regulator. Such derivatives control crown gall on grapevines. In addition, these derivatives did not induce roots necrosis but enhanced root development and callus formation. On young stem explants, it was shown as well that the F2/5 derivatives are necrosis-negative.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 16, 2015
    Applicant: Cornell University
    Inventors: Thomas J. Burr, Desen Zheng
  • Publication number: 20150104476
    Abstract: The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.
    Type: Application
    Filed: September 16, 2014
    Publication date: April 16, 2015
    Applicant: CUREVAC GMBH
    Inventors: Florian VON DER MÜLBE, Ingmar HOERR, Steve PASCOLO
  • Patent number: 8999667
    Abstract: The invention provides a DNA molecule comprising a multicistronic transcription unit coding for i) a polypeptide of interest, and for ii) a selectable marker polypeptide functional in a eukaryotic host cell, wherein the polypeptide of interest has a translation initiation sequence separate from that of the selectable marker polypeptide, and wherein the coding sequence for the polypeptide of interest is upstream from the coding sequence for the selectable marker polypeptide in the multicistronic transcription unit, and wherein an internal ribosome entry site is present downstream from the coding sequence for the polypeptide of interest and upstream from the coding sequence for the selectable marker polypeptide, and wherein the nucleic acid sequence coding for the selectable marker polypeptide in the coding strand comprises a GTG or a TTG start codon. Also provided are methods for obtaining host cells expressing a polypeptide of interest, such host cells comprising DNA molecules of the invention.
    Type: Grant
    Filed: September 6, 2007
    Date of Patent: April 7, 2015
    Assignee: Chromagenics B.V.
    Inventors: Arie P. Otte, Theodorus H. J. Kwaks, Henricus J. M. van Blokland, Richard G. A. B. Sewalt
  • Patent number: 8999669
    Abstract: The present invention relates to a nucleic acid molecule encoding a polypeptide specifically binding to proliferating cell nuclear antigen (PCNA). The present invention also relates to a vector comprising the nucleic acid molecule of the invention, a host cell comprising the nucleic acid molecule of or the vector of the invention and a method of detecting the amount and/or location of PCNA in living cells, a method of screening for compounds having an effect on the cell cycle.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: April 7, 2015
    Assignee: Ludwig-Maximilians Universitat München
    Inventors: Ulrich Rothbauer, Heinrich Leonhardt, Kourosh Zolghadr, Tina Romer, Katrin Schmidthals
  • Patent number: 8999641
    Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors with additional functional domains. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: April 7, 2015
    Assignees: The Broad Institute Inc., Maassachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng Zhang, Le Cong, Randall Jeffrey Platt, Neville Espi Sanjana
  • Publication number: 20150093414
    Abstract: Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis.
    Type: Application
    Filed: December 2, 2014
    Publication date: April 2, 2015
    Inventors: Normand BLAIS, Anne-Marie GELINAS, James BROWN, Dennis MURPHY, Pascal METTENS
  • Publication number: 20150093413
    Abstract: The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of infectious diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a pathogenic antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.
    Type: Application
    Filed: February 15, 2013
    Publication date: April 2, 2015
    Applicant: CureVac GmbH
    Inventors: Andreas Thess, Thomas Schlake, Jochen Probst
  • Publication number: 20150093766
    Abstract: There is provided a diagnostic reagent useful to determine whether an animal has a tuberculosis infection or has been exposed to a tuberculosis agent, for example a Mycobacterium. The reagent is useful to distinguish between such an animal and an animal which has been vaccinated against a tuberculosis infection.
    Type: Application
    Filed: September 23, 2014
    Publication date: April 2, 2015
    Inventors: Gareth JONES, Hans VORDERMEIER
  • Patent number: 8993275
    Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: March 31, 2015
    Assignee: Novozymes, Inc.
    Inventor: Nikolaj Spodsberg
  • Patent number: 8993839
    Abstract: Described herein are viral amplicon-based protein expression systems and methods useful for producing heterologous proteins, such as enzymes, by agroinfiltration. The methods involve producing an Agrobacterium with a Ti plasmid encoding a heterologous protein, infecting plant cells with the Agrobacterium, allowing expression of the heterologous protein, and recovering the heterologous protein from the plant cells. In one embodiment, the protein produced is an endoglucanase.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: March 31, 2015
    Assignee: The Regents of the University of California
    Inventors: Minsook Hwang, Benjamin E. Lindenmuth, Karen A. McDonald, Abhaya M. Dandekar, Bryce W. Falk, Sang-Kyu Jung, Nathaniel J. Kingsbury
  • Patent number: 8993233
    Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors with additional functional domains. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: March 31, 2015
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng Zhang, Le Cong, Randall Jeffrey Platt, Neville Espi Sanjana, Fei Ran
  • Publication number: 20150087546
    Abstract: The invention relates to a sequence, a technique platform, and a method for in vitro detecting Clostridium difficile ribotype 027. The technology platform includes a pair of primers specific to C. difficile ribotype 027 and used for polymerase chain reaction (PCR), and primer sets as well as materials demanded for multiplex-PCR. The method comprises steps of obtaining a specimen DNA, in vitro amplifying the specimen DNA by the primer sets to detect whether the specimen is matched to characteristics of a target sequence of SEQ ID NO: 1. Specimen having a sequence matching to characteristics indicates that it comprises C. difficile ribotype 027. Accordingly, the present invention can achieve the aim at quickly confirming whether the specimen contains ribotype 027 strains.
    Type: Application
    Filed: September 24, 2014
    Publication date: March 26, 2015
    Inventors: PEI-JANE TSAI, BO-YANG TSAI, YUAN-PIN HUNG, WEN-CHIEN KO
  • Patent number: 8987194
    Abstract: A Nisin derivative or variant, comprising an amino acid substitution at amino acid position 29 in the amino acid sequence. The Nisin derivative exhibits enhanced antimicrobial activity when compared to wild type Nisin. The Nisin derivative has an application as a natural food additive and as a therapeutic agent.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: March 24, 2015
    Assignees: University College Cork-National University of Ireland, Cork, Agriculture and Food Development Authority
    Inventors: Colin Hill, Paul Cotter, Paul R. Ross, Desmond Field
  • Patent number: 8986710
    Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: March 24, 2015
    Assignee: Pfizer Inc.
    Inventors: Annaliesa Sybil Anderson, Susan Kay Hoiseth, Kathrin Ute Jansen, Justin Keith Moran, Mark E. Ruppen
  • Publication number: 20150079209
    Abstract: The present invention provides a diabetes-inducing bacterium and use thereof, and a reagent and a detection method for detecting the bacterium. According to the present invention, enteric colonization of the diabetes-inducing bacterium can be prevented, and diabetes can be treated and/or prevented.
    Type: Application
    Filed: September 26, 2014
    Publication date: March 19, 2015
    Applicant: AJINOMOTO CO., INC.
    Inventors: Keishi KAMEYAMA, Kikuji Itoh
  • Publication number: 20150079602
    Abstract: The present invention refers to methods for selectively recognizing a base pair in a DNA sequence by a polypeptide, to modified polypeptides which specifically recognize one or more base pairs in a DNA sequence and, to DNA which is modified so that it can be specifically recognized by a polypeptide and to uses of the polypeptide and DNA in specific DNA targeting as well as to methods of modulating expression of target genes in a cell.
    Type: Application
    Filed: January 13, 2014
    Publication date: March 19, 2015
    Inventors: Ulla Bonas, Jens Boch, Sebastian Schornack, Thomas Lahaye
  • Patent number: 8980587
    Abstract: A bacterium belonging to the genus Streptomyces having an ability to produce reveromycin A or a synthetic intermediate thereof, the bacterium being modified so as to increase expression of revQ gene coding for the amino acid sequence of SEQ ID NO: 36 or an amino acid sequence having an identity of not less than 80% to SEQ ID NO: 36 as compared with a parent strain, thereby the above-mentioned production ability is increased as compared with the parent strain.
    Type: Grant
    Filed: August 30, 2011
    Date of Patent: March 17, 2015
    Assignee: RIKEN
    Inventors: Hiroyuki Osada, Shunji Takahashi, Makoto Kawatani, Yoshiyuki Sakaki, Atsushi Toyoda
  • Publication number: 20150071957
    Abstract: The present invention relates to Roseburia flagellin, and/or a polynucleotide sequence encoding said Roseburia flagellin, and/or a vector comprising said polynucleotide sequence, and/or a host cell, including bacteria, comprising said vector, and/or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.
    Type: Application
    Filed: April 10, 2014
    Publication date: March 12, 2015
    Inventors: Denise Kelly, Angela Patterson, Edouard Monnais, Imke Mulder
  • Patent number: 8974798
    Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: March 10, 2015
    Assignee: Zoetis P&U LLC
    Inventors: David E. Lowery, Troy E. Fuller, Michael J. Kennedy
  • Publication number: 20150064207
    Abstract: There is provided an epsilon toxin epitope polypeptide comprising a sequence of at least 10 contiguous amino acids from SEQ ID NO:3, the sequence comprising a mutation of at least one tyrosine residue compared to the equivalent sequence in SEQ ID NO:3, the polypeptide being capable of binding an antibody which binds to SEQ ID NO:5 and having reduced toxicity compared with the toxicity of SEQ ID NO:5. The polypeptide is useful in a method of vaccinating a subject against developing a disease caused by Clostridium perfringens and/or caused by (or associated with the presence of) active epsilon toxin.
    Type: Application
    Filed: March 28, 2013
    Publication date: March 5, 2015
    Inventors: Richard W. Titball, Monika Bokori-Brown, Claire Naylor
  • Patent number: 8968719
    Abstract: The invention relates to Salmonella typhi Ty21a comprising core-linked Shigella dysenteriae serotype 1 O-specific polysaccharide (O-Ps) and DNA encoding O antigen biosynthesis, said DNA selected from the group consisting of: a) the DNA sequence set out in any one of SEQ ID NOs: 1 and 2 and species homologs thereof; b) DNA encoding Shigella dysenteriae serotype 1 polypeptides encoded by any one of SEQ ID NOs: 1 and 2, and species homologs thereof; and c) DNA encoding a O antigen biosynthesis gene product that hybridizes under moderately stringent conditions to the DNA of (a) or (b); and related sequences, compositions of matter, vaccines, methods of using, and methods of making.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: March 3, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Sevices
    Inventors: Dennis J. Kopecko, De-Qi Xu
  • Publication number: 20150056240
    Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant.
    Type: Application
    Filed: August 22, 2014
    Publication date: February 26, 2015
    Inventors: Olaf SCHNEEWIND, Alice G. Cheng, Dominique M. Missiakas, Hwan Keun Kim
  • Publication number: 20150056646
    Abstract: Genetically-engineered cyanochrome fluorophore molecules (fluorophores) with increased fluorescence and with absorbing fluorescence in the blue and green (blue/green) portion of the light spectrum are provided. These fluorophores are derived from the domains of phytochromes, and in particular cyanobacterial phytochromes. Methods for generating these fluorophores and various applications of these fluorophores are also provided.
    Type: Application
    Filed: August 21, 2014
    Publication date: February 26, 2015
    Inventors: Andrew T. Ulijasz, Richard D. Vierstra
  • Patent number: 8962297
    Abstract: The present invention relates to isolated Clostridium perfringens bacteriophage lytic enzymes from baccteriophages CP26F and CP39O, and uses in controlling Clostridium perfringens.
    Type: Grant
    Filed: September 1, 2010
    Date of Patent: February 24, 2015
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Bruce S. Seal, Gregory R. Siragusa, Ibn Mustafa A. Simmons, Johnna K. Garrish, David M. Donovan
  • Publication number: 20150051146
    Abstract: A ligand recombinant protein inhibiting HB-EGF (Heparin-Binding Epidermal Growth Factor like), from the R domain of diphtheria toxin, which can be used for the treatment and diagnosis of diseases involving the activation of the HB-EGF/EGFR pathway.
    Type: Application
    Filed: March 19, 2013
    Publication date: February 19, 2015
    Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALT
    Inventors: Daniel Gillet, Benoit Villiers, Sylvain Pichard, Bernard Maillere, Alain Sanson
  • Patent number: 8956838
    Abstract: The present invention relates to a polynucleotide encoding an enzyme having carboxyl esterase [E.C. 2.1.1.1] activity.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: February 17, 2015
    Assignee: B.R.A.I.N.
    Inventors: Christian Elend, Karl-Erich Jaeger, Christian Leggewie, Christel Vollstedt, Wolfgang Streit
  • Patent number: 8956849
    Abstract: Vaccines comprising TRAP polypeptides and Salmonella enteritidis vectors comprising TRAP polypeptides are provided. The vaccines may also include a CD154 polypeptide capable of binding to CD40. Also provided are methods of enhancing an immune response against Apicomplexan parasites and methods of reducing morbidity associated with infection with Apicomplexan parasites.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: February 17, 2015
    Assignees: The Board of Trustees of the University of Arkansas, The Texas A&M University System, The University of Guelph
    Inventors: Walter Bottje, Billy Hargis, Luc Berghman, Young Min Kwon, Kimberly Cole, Mandy Cox, Sherryll Layton, Said El-Ashram, John Barta, Guillermo Tellez
  • Publication number: 20150044735
    Abstract: The biosynthesis of fungal bicyclo[2.2.2]diazaoctane indole alkaloids with a wide spectrum of biological activities have attracted increasing interest. Their intriguing mode of assembly has long been proposed to feature a non-ribosomal peptide synthetase, a presumed intramolecular Diels-Alderase, a variant number of prenyltransferases, and a series of oxidases responsible for the diverse tailoring modifications of their cyclodipeptide-based structural core. Until recently, the details of these biosynthetic pathways have remained largely unknown due to lack of information on the fungal derived biosynthetic gene clusters. Herein, we report a comparative analysis of four natural product metabolic systems of a select group of bicyclo[2.2.2]diazaoctane indole alkaloids including (+)/(?)-notoamide, paraherquamide and malbrancheamide, in which we propose an enzyme for each step in the biosynthetic pathway based on deep annotation and on-going biochemical studies.
    Type: Application
    Filed: April 3, 2013
    Publication date: February 12, 2015
    Inventors: Shengying Li, Krithika Anand Srinivasan, Robert M. Williams, David H. Sherman
  • Publication number: 20150045536
    Abstract: The present invention concerns an universal polypeptidic carrier for targeting directly or indirectly a molecule to Gb3 receptor expressing cells and having the following formula STxB-Z(n)-Cys, wherein: STxB is the Shiga Toxin B subunit or a functional equivalent thereof, Z is an amino-acid devoided of sulfydryl group, n being 0, 1 or a polypeptide, Cys is the amino-acid Cysteine, and the use thereof for MHC class I and MHC class II presentation of antigens.
    Type: Application
    Filed: September 5, 2014
    Publication date: February 12, 2015
    Inventors: Ludger JOHANNES, Eric TARTOUR, Bruno GOUD, Wolf Herve FRIDMAN